Thymidine Phosphorylase Inhibitors Market
Number of pages: 100 | Report Format: PDF | Published date: April 27, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
CAGR |
7.73% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Application, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global thymidine phosphorylase inhibitors market is expected to grow at a revenue CAGR of 7.73% from 2023 to 2031.
Thymidine Phosphorylase Inhibitors Market Fundamentals
Thymidine phosphorylase inhibitors are a group of drugs used to treat types of cancer, including colon, rectal, gastric, and esophageal cancer that has spread to other parts of the body, particularly in patients who have already received chemotherapy or are not suitable for it. The main mechanism of action of thymidine phosphorylase inhibitors is to block the activity of the thymidine phosphorylase enzyme. This enzyme is involved in the metabolism of purines, the salvage pathway of pyrimidine nucleosides, and the regulation of angiogenesis. It is found in higher levels in many solid tumors than normal tissues and promotes tumor growth and metastasis. By inhibiting the activity of this enzyme, thymidine phosphorylase inhibitors can suppress tumor growth, increase cell death, and limit the formation of new blood vessels in tumors, which are required for their growth and spread. Thymidine phosphorylase inhibitors are a promising area of research in cancer treatment, but more studies are necessary to determine their safety and effectiveness in larger clinical trials.
Thymidine Phosphorylase Inhibitors Market Dynamics
The prevalence of cancer is growing globally due to various factors such as aging populations, lifestyle changes, and exposure to risk factors such as tobacco use and pollution. As a result, the demand for effective cancer treatments, including thymidine phosphorylase inhibitors, is growing. Traditional chemotherapy is known to have significant side effects due to its inability to differentiate between healthy and cancerous cells. Targeted cancer therapies, such as thymidine phosphorylase inhibitors, are designed to selectively target cancer cells, reduce side effects, and improve treatment outcomes. The growing need for targeted cancer therapies is increasing the development and adoption of drugs like thymidine phosphorylase inhibitors. Thymidine phosphorylase inhibitors are combined with other cancer treatments, such as chemotherapy or radiation therapy, to improve treatment outcomes. This combination therapy approach is being explored in clinical trials and may become a significant thymidine phosphorylase inhibitors market trend.
Moreover, pharmaceutical companies are increasing their investment in the research and development of thymidine phosphorylase inhibitors. Thymidine phosphorylase inhibitors are being developed with a focus on personalized medicine, where treatments are tailored to the individual patient's genetic makeup, disease type, and cancer stages. Technological advancements, such as next-generation sequencing, are facilitating the development of targeted cancer therapies which is also expected to fuel the thymidine phosphorylase inhibitors market growth.
However, there are some side effects associated with thymidine phosphorylase inhibitors, such as nausea, vomiting, diarrhea, and abdominal pain which is restricting the thymidine phosphorylase inhibitors market growth. Targeted cancer therapies, including thymidine phosphorylase inhibitors, can be expensive. The high cost of treatment may limit patient access, particularly in low- and middle-income countries. Thymidine phosphorylase inhibitors have shown limited efficacy as monotherapy in clinical trials, leading to the development of combination therapies. These combinations increase the risk of toxicity, hampering the thymidine phosphorylase inhibitors' market growth.
Thymidine Phosphorylase Inhibitors Market Ecosystem
The global thymidine phosphorylase inhibitors market is analyzed from three perspectives: application, distribution channel, and region.
Thymidine Phosphorylase Inhibitors Market by Application
[23]
Based on the application, the global thymidine phosphorylase inhibitors market is segmented into metastatic colorectal cancer, gastric cancer, esophageal cancer, and others.
The metastatic colorectal cancer segment accounted for the largest revenue share of the thymidine phosphorylase inhibitors market in 2022. Colorectal cancer is the third most commonly diagnosed cancer worldwide. This high incidence of metastatic colorectal cancer drives demand for effective treatments like thymidine phosphorylase inhibitors. According to the WHO, in 2020, almost 2 million cases of colorectal cancer were diagnosed. It is the second most common cause of cancer death, leading to almost 1 million deaths per year. Historically, chemotherapy has been the primary treatment for metastatic colorectal cancer but is associated with significant toxicity and limited efficacy. Thymidine phosphorylase inhibitors offer a targeted treatment option with potentially fewer side effects and improved outcomes. Thymidine phosphorylase inhibitors have been approved for treating metastatic colorectal cancer for over a decade, and they have a well-established market and clinical evidence base. Thymidine phosphorylase inhibitors are often used in combination with other agents, such as chemotherapy or immunotherapy, to improve outcomes. This has further expanded the use of thymidine phosphorylase inhibitors for metastatic colorectal cancer.
The gastric cancer segment accounted for a considerable thymidine phosphorylase inhibitors market share in 2022. There is a rise in the number of cancer cases globally, and it is the fifth most common cancer worldwide. This high incidence drives demand for effective treatments like thymidine phosphorylase inhibitors. According to the WHO, in 2020, approximately 1.09 million gastric cancer cases were diagnosed worldwide, it accounted for 769,000 deaths. The most common therapy for advanced or metastatic gastric cancer is chemotherapy, although it has a high rate of toxicity and only modest efficacy. Thymidine phosphorylase inhibitors present a focused, therapeutic alternative with perhaps fewer adverse effects and better results. Thymidine phosphorylase inhibitors are frequently combined with other medications, such as chemotherapy or targeted therapies, to improve results. As a result, the usage of thymidine phosphorylase inhibitors in the treatment of stomach cancer has increased. A growing pipeline of thymidine phosphorylase inhibitors is in development for gastric cancer, which is expected to drive growth in the market. This includes new formulations, combination therapies, and novel mechanisms of action.
Thymidine Phosphorylase Inhibitors Market by Distribution Channel
Based on the distribution channel, the global thymidine phosphorylase inhibitors market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies.
The hospital pharmacies segment accounted for the prominent revenue share of the thymidine phosphorylase inhibitors market. Thymidine phosphorylase inhibitors are medications that require careful monitoring and management. Hospitals have the infrastructure and resources to provide the necessary support, including the ability to monitor these drugs safely. Patients with advanced cancer, such as metastatic colorectal cancer, often require hospitalization for treatment. Hospitals are equipped to provide the comprehensive care these patients need, including administering thymidine phosphorylase inhibitors. Hospitals often have specialized oncology and hematology services that can provide additional support and management for patients receiving thymidine phosphorylase inhibitors. This includes access to supportive care services like nutritional counseling, pain management, and psychological support. The cost of thymidine phosphorylase inhibitors can be high, and insurance coverage and reimbursement can be complex. Hospitals are experienced in navigating the insurance and reimbursement process, making obtaining coverage for these drugs easier.
The retail pharmacies segment accounted for a significant thymidine phosphorylase inhibitors market share in 2022.Retail pharmacies are widely distributed and easily accessible, making them a convenient option for patients who require regular dosing of thymidine phosphorylase inhibitors. Patients can visit their local pharmacy to pick up their medication and receive counseling from a pharmacist. Retail pharmacies may offer lower prices for thymidine phosphorylase inhibitors than hospitals or specialized cancer centers. This can make them a more affordable option for patients paying out of pocket or with limited insurance coverage. In some cases, prescribers may choose to prescribe thymidine phosphorylase inhibitors for patients to pick up at a retail pharmacy rather than a hospital. This may be due to factors such as patient preference, convenience, and insurance coverage.
Thymidine Phosphorylase Inhibitors Market by Region
Geographically, the global thymidine phosphorylase inhibitors market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
The North America region has the largest thymidine phosphorylase inhibitors market size in terms of revenue generation. North America has a relatively high incidence of cancer, which creates a large patient population for thymidine phosphorylase inhibitors. Colorectal, gastric, and esophageal cancers are among the most common types of cancer in the region. According to the American Cancer Society, in the U.S., there will be around 106,970 new colon cancer cases and 46,050 new cases of rectal cancer diagnosed in 2023. Thymidine phosphorylase inhibitors are targeted therapy that can be used to treat certain types of cancer. As targeted therapies become more widely accepted in North America, the use of thymidine phosphorylase inhibitors may increase as well. Advancements in technology are leading to the development of new thymidine phosphorylase inhibitors with improved efficacy and safety profiles. North America has many leading pharmaceutical companies and research institutions at the forefront of drug development. North America has a well-established regulatory framework for drug approval and a strong intellectual property system, which can encourage investment in drug development and support the commercialization of new therapies. The growing demand for personalized medicine in North America drives the popularity of treatments tailored to individual patients based on their genetic makeup and other factors. Thymidine phosphorylase inhibitors are well-suited for personalized medicine approaches, such as genetic testing and biomarker analysis, to enhance treatment outcomes. This trend presents an opportunity for developing and commercializing more effective and targeted thymidine phosphorylase inhibitors in the region.
The Asia Pacific region has a high burden of cancer, with countries like China, India, and Japan accounting for a significant proportion of global cancer cases. This drives the demand for effective cancer treatments, including thymidine phosphorylase inhibitors. Many countries in the Asia Pacific region are increasing their healthcare spending to improve access to quality care for their populations. This is leading to expanding healthcare facilities and adopting new treatments, including thymidine phosphorylase inhibitors. Governments in the region are taking steps to improve cancer care and reduce the burden of cancer on their populations. This includes initiatives to increase access to cancer treatments and reduce treatment costs, driving the growth of the thymidine phosphorylase inhibitors market in the region. There is increasing awareness about cancer and its early detection and treatment options in Asia.
Thymidine Phosphorylase Inhibitors Competitive Landscape
The prominent players operating in the global thymidine phosphorylase inhibitors market are:
Thymidine Phosphorylase Inhibitors Strategic Developments
Thymidine phosphorylase inhibitors are a type of drug that can inhibit the activity of the thymidine phosphorylase enzyme, which plays a role in the formation of new blood vessels (angiogenesis). What will be the CAGR of the thymidine phosphorylase inhibitors market during the forecast period? The global thymidine phosphorylase inhibitors market growth is estimated to be at a revenue CAGR of 7.73%.
The prominent players operating in the global thymidine phosphorylase inhibitors market are Taiho Oncology, Inc. (Taiho Pharmaceutical Co., Ltd.), Les Laboratoires Servier, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., and Elevar Therapeutics among others.
North America has the largest market share in terms of revenue, and Asia Pacific has the fastest growth rate.
The metastatic colorectal cancer segment dominated the global thymidine phosphorylase inhibitors market.
*Insights on financial performance are subject to the availability of information in the public domain